Choroidal Neovascularization (CNV) Market: By Treatment Type (Angiogenesis Inhibitors Injection, Photodynamic Therapy, Laser photocoagulation, Low-dose, Radiation Therapy, Surgery), By Diagnosis Types & By Geography - Forecast (2016 - 2021)

  • ID: 3920034
  • Report
  • 139 pages
  • IndustryARC
1 of 3
Choroidal Neovascularization (CNV) is rapidly occurring in the population with defects in the innermost layer of the choroid called Bruch's membrane. It is associated with generation of new blood vessels in the choroidal layer of eye. These blood vessels abruptly break into the retina and cause disruption and sight loss/vision loss. The major signs and symptoms of this disorder are loss of vision, Metamorphopsia, paracentral or central scotoma, and apparent change in image size. This disease mostly occurs in aged group of population and people with severe myopia.

There are several methods for the diagnosis of Choroidal Neovascularization (CNV) including Fluorescein Angiography (FA), Indocyanine Green (ICG) angiography , and spectral domain Optical Coherence Tomography (OCT). Fluorescein Angiography (FA) is most commonly used diagnosis methods. Nowadays, spectral domain OCT has largely replaced FA owing to its advantages and highly precise diagnosis. In view of the fact that CNV often initiate from posterior pole lesions and hence is hard to detect. A very accurate and precise diagnosis is obligatory to get rid of CNV. The report covers detailed analysis of all types of diagnosis methods of CNV along with the various treatments. The major treatments of CNV are angiogenesis inhibitors injection, photodynamic therapy, laser photocoagulation, low dose radiation therapy, and surgery. The angiogenesis inhibitor injection is the conventional method to control the growth of blood vessels by reducing the area of fluid below the retinal pigment epithelium.

The report includes the major market dynamic factors such as drivers, restraints, challenges and opportunities and their impact on the industry in next 5 years. The high rate of increase in CNV affected patients due to increasing aged population is the major factor driving the growth of this market. Governments and heath care departments across the world are taking initiatives towards spreading awareness about the disease and providing diagnosis and treatments at affordable prices. This is also helping in driving the growth of CNV detection and treatment market. However, high lack of awareness among people majorly in the African and Asian regions about different types of eye diseases and high cost associated with its treatment are the major factors inhibiting the growth of this market. Moreover, unavailability of good healthcare infrastructure, better facilities and high grade care of patients are still some of the major challenges in this market.

Choroidal Neovascularization (CNV) Market

The report identifies and analyzes the key industry factors affecting the revenue generation in the CNV treatment market. The report tracks the entire value chain of the market along with the suppliers and distributor analysis. Moreover, the industry attractiveness section in the offers the significance of the competitive rivalry in the market affected by the forces such as power of supplier, power of buyer, threat of new entrant and threat of substitution. The report provides precise and comprehensive insights on the market trends, industry trends, and macro & micro factors impacting the market growth.

Major geographies of North America, Europe, Asia-Pacific, and Latin America are tracked and analyzed in the report. Due to the large number of aged population in North America, the region is estimated to be highly affected by this disease. Asia-Pacific region is expected to grow with high rate in next 5 years majorly in the countries of China, and India.
The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players.

The major players profiled in the report include:
Bayer AG
Chengdu Kanghong Biotech Co. Ltd
Resolvyx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Valeant Pharmaceuticals International Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Market Overview
2. Executive Summary
3. Choroidal Neovascularization (CNV) Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. End-User Profiling
3.2.2. Patent Analysis
3.2.3. Financial Analysis of Top 5 Players
4. Choroidal Neovascularization (CNV) Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of Industry
4.4.1. Power of Supplier
4.4.2. Power of Consumer
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Choroidal Neovascularization (CNV) Market Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunity Analysis
5.4. Product Life Cycle Analysis
5.5. Suppliers & Distributors
6. Choroidal Neovascularization (CNV) Market Analysis - By Treatment Type
6.1. Angiogenesis Inhibitors Injection
6.2. Photodynamic Therapy
6.3. Laser photocoagulation
6.4. Low-dose Radiation Therapy
6.5. Surgery
7. Choroidal Neovascularization (CNV) Market Analysis - By Type of Diagnosis
7.1. Fluorescein angiography (FA)
7.2. Indocyanine green (ICG) angiography
7.3. Spectral domain optical coherence tomography (OCT)
7.4. Others
8. Choroidal Neovascularization (CNV) Market Analysis - By Geography
8.1. North America
8.1.1. The U.S.
8.1.2. Canada
8.1.3. Rest of North America
8.2. Europe
8.2.1. The U.K.
8.2.2. Germany
8.2.3. France
8.2.4. Spain
8.2.5. Italy
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. Australia
8.3.5. Rest of APAC
8.4. Latin America
8.4.1. Brazil
8.4.2. Argentina
8.4.3. Mexico
8.4.4. Rest of Latin America
8.5. Rest of the World
8.5.1. The Middle East
8.5.2. Africa
9. Choroidal Neovascularization (CNV) Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, Partnerships & JVs
10. Company Profiles (Overview, Financials, Products & Services, Recent Developments, Competitors & Customers)
10.1. Pfizer Inc.
10.2. F. Hoffmann-La Roche Ltd.
10.3. Novartis AG
10.4. Regeneron Pharmaceuticals Inc.
10.5. Bayer AG
10.6. QLT Inc.
10.7. Sanwa Kagaku Kenkyusho Co. Ltd.
10.8. Promedior Inc.
10.9. Valeant Pharmaceuticals International Inc.
10.10. Gilead Sciences Inc

"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown